Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia

Immunology

Volumn 119, Issue 4, 2006, Pages 507-514

  Passmore, Jo Ann S ^a,c   Milner, Michelle ^a   Denny, Lynnette ^a   Sampson, Candice ^a   Marais, Dianne J ^a   Allan, Bruce ^a   Gumbi, Pam P ^a   Hitzeroth, Inga I ^a   Rybicki, Edward P ^a   Williamson, Anna Lise ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Cervical; Human papillomavirus; Mucosal; T cell immunity

Indexed keywords

CAPSID PROTEIN; CAPSID PROTEIN L1; GAMMA INTERFERON; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; PRIORITY JOURNAL; STAINING; T LYMPHOCYTE; UTERINE CERVIX; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS PARTICLE; VIRUS REPLICATION;

ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; COHORT STUDIES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INTERFERON TYPE II; LEUKOCYTE L1 ANTIGEN COMPLEX; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; T-LYMPHOCYTE SUBSETS; UTERINE CERVICAL NEOPLASMS;

EID: 33750882747     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2006.02465.x     Document Type: Article

References (23)

1. Bosch FX, Munoz N. The viral etiology of cervical cancer. Virus Res 2002; 89:183-9.
2. Kay P, Soeters R, Nevin J, Denny L, Dehaeck CM, Williamson A. High prevalence of HPV 16 in South African women with cancer of the cervix and cervical intraepithelial neoplasia. J Med Virol 2003; 71:265-73.
3. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27.
4. Evander M, Edlund K, Gustafsson A, Jonsson M, Karlsson R, Rylander E, Wadell G. Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 1995; 171:1026-30.
5. Herrero R, Hildesheim A, Bratti C et al. Population based study of HPV infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2002; 92:464-74.
6. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. New Engl J Med 1998; 338:423-8.
7. Pinto AP, Crum CP. Natural history of cervical neoplasia. defining progression and its consequence. Clin Obstet Gynecol 2000; 43:352-62.
8. Bontkes HJ, de Gruijl TD, Walboomers JMM et al. Immune responses against HPV type 16 VLPs in a cohort study of women with CIN, II. Systemic but not local IgA responses correlate with clearance of HPV-16. J Gen Virol 1999; 80:409-17.
9. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004; 4:46-54.
10. Tindle RW. Immune evasion in HPV-associated cervical cancer. Nat Rev Cancer 2002; 2:59-65.
11. Nicholls PK, Moore PF, Anderson DM, Moore RA, Parry NR, Gough GW, Stanley MA. Regression of canine oral papillomavirus is associated with infiltration of CD4 and CD8 lymphocytes. Virology 2001; 283:31-9.
12. Stanley M. Immunobiology of papillomavirus infections. J Reprod Immunol 2001; 52:45-59.
13. Marais DJ, Rose RC, Williamson A. Age distribution of antibodies to human papillomavirus in children, women with cervical intraepithelial neoplasia and blood donors from South Africa. J Med Virol 1997; 51:126-31.
14. Passmore JS, Burch V, Shephard EV, Marais DJ, Allan B, Kay P, Rose R, Williamson A. Single cell cytokine analysis allows detection of cervical T cell responses against human papillomavirus (HPV) type 16, L1 in women infected with genital HPV. J Med Virol 2002; 67:234-40.
15. Yan M, Peng J, Jabbar IA, Liu X, Filgueira L, Frazer IH, Thomas R. Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells 2004. Virology 2004; 324:297-310.
16. Rudolf MP, Nieland JD, DaSilva DM, Velders MP, Muller M, Greenstone HL, Schiller JT, Kast WM. Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles. Biol Chem 1999; 380:335-40.
17. + cytotoxic T lymphocytes. J Virol 2003; 77:291-300.
18. + T-lymphocyte responses in blood and mucosa during chronic infection. J Virol 2005; 79:4289-97.
19. Miller CJ, Li Q, Abel K et al. Propagation and dissemination of infection after vaginal transmission of SIV. J Virol 2005; 79:9217-27.
20. Brandtzaeg P, Farstad IN, Haraldsen G. Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol Today 1999; 20:267-77.
21. + T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: too late and too little. J Virol 2005; 79:9228-35.
22. Bontkes HJ, de Gruijl TD, Walboomers JMM, van den Muysenberg AJ, Gunther AW, Scheper RJ, Meijer CJ, Kummer JA. Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions. Br J Cancer 1997; 76:1353-60.
23. Kobayashi A, Greenblatt RM, Anastos K et al. Functional attributes of mucosal immunity in CIN and effects of HIV infection. Cancer Res 2004; 64:6766-74.